Ann: Vitura Health joining S&P/ASX All Ordinaries Index, page-41

I think so, if VIT can make the process seamless for both the HCP and the patient then there is still growth in market share to be had alongside the organic growth they'll get from increasing patient numbers in Aus. Looking at their roadmap I would say they are on the right track.

There are only two companies I would park my money in at the moment in this space. One is definitely VIT, however I currently have everything parked in the other one (ECS). Not entirely apples to apples though, VIT's strength is it's tech platform and distribution network while ECS is it's ability to cultivate at a ridiculously low cost (AUD 20c per gram).